CVS Health Corporation $CVS Shares Sold by Continuum Advisory LLC

Key Points

• Continuum Advisory LLC cut its CVS Health stake by 98.8% in the second quarter, selling 79,745 shares and retaining 991 shares valued at approximately $103,000.
• Analysts remain broadly bullish, with 22 Buy ratings and one Hold rating; CVS has a consensus “Moderate Buy” rating and an average price target of $106.83.
• CVS reported strong quarterly results, earning $2.58 per share versus the $1.87 estimate and generating $106.1 billion in revenue, up 7.3% year over year. The company also maintains a $0.665 quarterly dividend, yielding about 2.7% annually.

Continuum Advisory LLC lessened its holdings in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 98.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 991 shares of the pharmacy operator's stock after selling 79,745 shares during the period. Continuum Advisory LLC's holdings in CVS Health were worth $103,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd raised its stake in shares of CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after purchasing an additional 281 shares in the last quarter. Swiss RE Ltd. bought a new position in CVS Health in the 4th quarter valued at about $26,000. Kilter Group LLC acquired a new position in CVS Health during the 2nd quarter valued at about $27,000. Sankala Group LLC bought a new stake in shares of CVS Health during the 4th quarter worth about $28,000. Finally, Global Trust Asset Management LLC raised its position in shares of CVS Health by 344.8% during the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator's stock worth $28,000 after buying an additional 300 shares in the last quarter. 80.66% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on CVS. Mizuho increased their price objective on shares of CVS Health from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Monday, June 8th. Piper Sandler restated an "overweight" rating on shares of CVS Health in a research report on Wednesday, August 26th. Bank of America increased their price target on CVS Health from $100.00 to $110.00 and gave the company a "buy" rating in a research note on Monday, June 22nd. Cantor Fitzgerald boosted their price objective on CVS Health from $100.00 to $110.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 7th. Finally, Truist Financial upped their price objective on CVS Health from $108.00 to $118.00 and gave the company a "buy" rating in a report on Tuesday, July 14th. Twenty-two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $106.83.

CVS Health Trading Up 0.1%

Shares of NYSE:CVS opened at $96.80 on Tuesday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The stock has a market capitalization of $123.80 billion, a price-to-earnings ratio of 25.61, a PEG ratio of 0.94 and a beta of 0.59. CVS Health Corporation has a 1-year low of $69.51 and a 1-year high of $110.68. The company has a 50 day moving average price of $100.65 and a 200 day moving average price of $90.35.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The company had revenue of $106.10 billion for the quarter, compared to analysts' expectations of $100.03 billion. During the same quarter in the prior year, the company earned $1.81 earnings per share. The firm's revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, research analysts anticipate that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were paid a $0.665 dividend. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.7%. CVS Health's dividend payout ratio (DPR) is currently 70.37%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.